Capsugel Unveils Quality Control Laboratory
News Dec 10, 2012
Capsugel has announced that it has doubled its laboratory capacity with the opening of its new Quality Control Laboratory in Greenwood, SC.
The new laboratory serves as a global resource to its extensive network of manufacturing sites and R&D laboratories located in Boston, Strasbourg and Colmar.
The company invested more than $3 million to create this facility that is the global center of excellence for quality control and testing of all raw materials and specialty testing of finished products for Capsugel sites around the world.
The facility’s opening marks a significant investment that demonstrates Capsugel’s commitment to designing, manufacturing, and delivering premiere healthcare products and services.
“Our new Quality Control Laboratory positions Capsugel for future growth in an increasingly complex regulatory marketplace,” says Guido Driesen, President & CEO of Capsugel.
Driesen continued, “Quality is the hallmark of our business and a core principle at Capsugel that provides added value to our customers. Our thorough testing equates to faster time to market as our products are designed to comply with today’s strict regulations.”
The 9,600 square foot facility is equipped to provide a wide range of analytical and microbial testing, as well as development of color formulations.
With the new capacity, Capsugel has expanded its Global Stability Program with walk-in stability chambers and photo stability chambers.
This critical equipment is used to support the shelf life of the finished products, to register new products in different countries, and to conduct excursion studies to determine the impact of different temperature and humidity conditions on the quality of the capsules.
By the time a product is considered ready for market, it may have gone through up to 23 individual quality tests at the company’s new Quality Control Laboratory.
The facility is the latest in a series of recent upgrades and expansions, as Capsugel grows to meet its increasing global demand for its high quality capsule products.
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018